Recombinant murine fibroblast growth factor 21 ameliorates obesity-related inflammation in monosodium glutamate-induced obesity rats
- 698 Downloads
The aim of this study is to investigate the role of FGF21 in obesity-related inflammation in livers of monosodium glutamate (MSG)-induced obesity rats. The MSG rats were injected with recombinant murine fibroblast growth factor 21(FGF21) or equal volumes of vehicle. Metabolic parameters including body weight, Lee’s index, food intake, visceral fat and liver weight, intraperitoneal glucose tolerance, glucose, and lipid levels were dynamically measured at specific time points. Liver function and routine blood test were also analyzed. Further, systemic inflammatory cytokines such as glucose transporter 1 (GLUT-1), leptin, TNF-α, and IL-6 mRNAs were determined by real-time PCR. FGF21 independently decreased body weight and whole-body fat mass without reducing food intake in the MSG rats. FGF21 reduced blood glucose level, Lee’s index, visceral fat, and liver weight, and improved glucose tolerance, lipid metabolic spectrum, and hepatic steatosis in the MSG-obesity rats. Liver function parameters including AST, ALT, ALP, TP, T.Bili, and D.Bili levels significantly reduced in the FGF21-treated obesity rats compared to the controls. Further, FGF21 ameliorated the total and differential white blood cell (WBC) count, serum C-reactive protein (CRP), IL-6, and TNF-α levels in adipose tissues of the obesity rats, suggesting inflammation amelioration in the in the obesity rats by FGF21. FGF21 improves multiple metabolic disorders and ameliorates obesity-related inflammation in the MSG-induced obesity rats.
KeywordsObesity Monosodium glutamate Fibroblast growth factor 21 Inflammation Rat
This study was supported by the National Natural Science Foundation of China (Nos.81172741 and 30972537).
Conflict of interest
The authors declare that there is no conflict of interest in this study.
- 11.N. Aoi, M. Soma, T. Nakayama, D. Rahmutula, K. Kosuge, Y. Izumi et al., Variable number of tandem repeat of the 5’-flanking region of type-C human natriuretic peptide receptor gene influences blood pressure levels in obesity-associated hypertension. Hypertens. Res. 27, 711–716 (2004)CrossRefPubMedGoogle Scholar
- 16.M. Rondanelli, A. Opizzi, S. Perna, M. Faliva, S.B. Solerte, M. Fioravanti, C. Klersy, E. Cava, M. Paolini, L. Scavone, P. Ceccarelli, E. Castellaneta, C. Savina, L.M. Donini, Improvement in insulin resistance and favourable changes in plasma inflammatory adipokines after weight loss associated with two months’ consumption of a combination of bioactive food ingredients in overweight subjects. Endocrine 44, 391–401 (2013)CrossRefPubMedCentralPubMedGoogle Scholar
- 19.T. Nakagawa, K. Ukai, T. Ohyama, Y. Gomita, H. Okamura, Effects of chronic administration of sibutramine on body weight, food intake and motor activity in neonatally monosodium glutamate-treated obese female rats: relationship of antiobesity effect with monoamines. Exp. Anim. 49, 239–249 (2000)CrossRefPubMedGoogle Scholar
- 27.Y.L. Zhang, A. Hernandez-Ono, P. Siri, S. Weisberg, D. Conlon, M.J. Graham et al., Aberrant hepatic expression of PPARgamma2 stimulates hepatic lipogenesis in a mouse model of obesity, insulin resistance, dyslipidemia, and hepatic steatosis. J. Biol. Chem. 281, 37603–37615 (2006)CrossRefPubMedGoogle Scholar
- 29.H. Wang, L. Qiang, S.R. Farmer, Identification of a domain within peroxisome proliferator-activated receptor gamma regulating expression of a group of genes containing fibroblast growth factor 21 that are selectively repressed by SIRT1 in adipocytes. Mol. Cell. Biol. 28, 188–200 (2008)CrossRefPubMedCentralPubMedGoogle Scholar